AstraZeneca CEO Says AI Improving Drug Development Success Rates

MT Newswires Live

Yesterday

AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the drugmaker develop medicines faster, optimize drug design, and improve decision-making across research and development, CNBC reported Friday.

Soriot said AI can help identify new drug targets, refine molecules and reduce potential side effects before clinical testing, boosting productivity throughout the development process.

He added that AstraZeneca's partnership with Tempus AI has led to the creation of an AI agent that analyzes clinical and laboratory data to predict the probability of success in Phase 3 trials.

"We spend $300 million, $400 million, $500 million on a trial," Soriot said. "If you increase the probability of success, the productivity improvement is enormous."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2641459123"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641459123\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641459123?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-06 07:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641459123","market":"us","top_or_hot":-1,"title":"AstraZeneca CEO Says AI Improving Drug Development Success Rates","media":"MT Newswires Live","content":"<html><body><p> AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the drugmaker develop medicines faster, optimize drug design, and improve decision-making across research and development, CNBC reported Friday.</p><p>Soriot said AI can help identify new drug targets, refine molecules and reduce potential side effects before clinical testing, boosting productivity throughout the development process.</p><p>He added that AstraZeneca's partnership with <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> has led to the creation of an AI agent that analyzes clinical and laboratory data to predict the probability of success in Phase 3 trials.</p><p>\"We spend $300 million, $400 million, $500 million on a trial,\" Soriot said. \"If you increase the probability of success, the productivity improvement is enormous.\"</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca CEO Says AI Improving Drug Development Success Rates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca CEO Says AI Improving Drug Development Success Rates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-06 07:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the drugmaker develop medicines faster, optimize drug design, and improve decision-making across research and development, CNBC reported Friday.</p><p>Soriot said AI can help identify new drug targets, refine molecules and reduce potential side effects before clinical testing, boosting productivity throughout the development process.</p><p>He added that AstraZeneca's partnership with <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> has led to the creation of an AI agent that analyzes clinical and laboratory data to predict the probability of success in Phase 3 trials.</p><p>\"We spend $300 million, $400 million, $500 million on a trial,\" Soriot said. \"If you increase the probability of success, the productivity improvement is enormous.\"</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4528","symbol_name":"SaaS概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641459123","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641459123","pubTimestamp":1780703873,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the drugmaker develop medicines faster, optimize drug design, and improve decision-making across research and development, CNBC reported Friday.Soriot said AI can help identify new drug targets, refine molecules and reduce potential side effects before clinical testing, boosting productivity throughout the development process.He added that AstraZeneca's partnership with Tempus AI has led to the creation of an AI agent that analyzes clinical and laboratory data to predict the probability of success in Phase 3 trials.\"We spend $300 million, $400 million, $500 million on a trial,\" Soriot said. \"If you increase the probability of success, the productivity improvement is enormous.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4528":"SaaS概念","AGIX":"通用人工智能 ETF-AGIX","AIPO":"Defiance AI and Power Infrastructure ETF","BK4023":"应用软件","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AI":"C3.ai, Inc.","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4543":"AI","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念"},"translate_title":"阿斯利康首席执行官表示人工智能提高了药物开发成功率","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":1.5,"AI":0.61,"ARTY":1.5,"CHAT":1.5,"AGIX":1.5,"AIYY":0.6},"content_text":"AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the drugmaker develop medicines faster, optimize drug design, and improve decision-making across research and development, CNBC reported Friday.Soriot said AI can help identify new drug targets, refine molecules and reduce potential side effects before clinical testing, boosting productivity throughout the development process.He added that AstraZeneca's partnership with Tempus AI has led to the creation of an AI agent that analyzes clinical and laboratory data to predict the probability of success in Phase 3 trials.\"We spend $300 million, $400 million, $500 million on a trial,\" Soriot said. \"If you increase the probability of success, the productivity improvement is enormous.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}